BACKGROUND AND OBJECTIVES: Atypical hemolytic uremic syndrome (aHUS) is associated with a congenital or acquired dysregulation of the complement alternative pathway that leads to continuous complement activation on host cells causing inflammation and damage. Eculizumab, a humanized mAb against complement protein C5, inhibits activation of the terminal complement pathway. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We report an adolescent with relapsing unclassified aHUS. On admission, a high plasma creatinine level indicated a poor prognosis, and hemodialysis had to be started. Plasma exchanges were initially effective against the microangiopathic hemolytic activity and allowed a temporary improvement of renal function with termination of hemodialysis after 7 wk. Subsequently, plasma exchanges (three times per week) failed to prevent ongoing aHUS activity and progressive renal failure. After 12 wk, aHUS treatment was switched to eculizumab. RESULTS: Eculizumab was effective in terminating the microangiopathic hemolytic process in two aHUS relapses; however, after normalization of complement activity, aHUS recurred and ultimately led to anuric end-stage renal failure. CONCLUSIONS: In this patient, complement inhibition by eculizumab temporarily terminated the microangiopathic hemolytic activity. Nevertheless, renal damage as a result of preceding and subsequent aHUS activity resulted in end-stage renal failure; therefore, therapeutic success may depend on early administration of eculizumab. The optimal duration of treatment may be variable and remains to be determined.
BACKGROUND AND OBJECTIVES:Atypical hemolytic uremic syndrome (aHUS) is associated with a congenital or acquired dysregulation of the complement alternative pathway that leads to continuous complement activation on host cells causing inflammation and damage. Eculizumab, a humanized mAb against complement protein C5, inhibits activation of the terminal complement pathway. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We report an adolescent with relapsing unclassified aHUS. On admission, a high plasma creatinine level indicated a poor prognosis, and hemodialysis had to be started. Plasma exchanges were initially effective against the microangiopathic hemolytic activity and allowed a temporary improvement of renal function with termination of hemodialysis after 7 wk. Subsequently, plasma exchanges (three times per week) failed to prevent ongoing aHUS activity and progressive renal failure. After 12 wk, aHUS treatment was switched to eculizumab. RESULTS:Eculizumab was effective in terminating the microangiopathic hemolytic process in two aHUS relapses; however, after normalization of complement activity, aHUS recurred and ultimately led to anuric end-stage renal failure. CONCLUSIONS: In this patient, complement inhibition by eculizumab temporarily terminated the microangiopathic hemolytic activity. Nevertheless, renal damage as a result of preceding and subsequent aHUS activity resulted in end-stage renal failure; therefore, therapeutic success may depend on early administration of eculizumab. The optimal duration of treatment may be variable and remains to be determined.
Authors: Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi Journal: Blood Date: 2006-04-18 Impact factor: 22.113
Authors: Jens Nürnberger; Thomas Philipp; Oliver Witzke; Anabelle Opazo Saez; Udo Vester; Hideo Andreas Baba; Andreas Kribben; Lothar Bernd Zimmerhackl; Andreas R Janecke; Mato Nagel; Michael Kirschfink Journal: N Engl J Med Date: 2009-01-29 Impact factor: 91.245
Authors: Gema Ariceta; Nesrin Besbas; Sally Johnson; Diana Karpman; Daniel Landau; Christoph Licht; Chantal Loirat; Carmine Pecoraro; C Mark Taylor; Nicole Van de Kar; Johan Vandewalle; Lothar B Zimmerhackl Journal: Pediatr Nephrol Date: 2008-09-18 Impact factor: 3.714
Authors: Marie-Agnès Dragon-Durey; Véronique Frémeaux-Bacchi; Chantal Loirat; Jacques Blouin; Patrick Niaudet; Georges Deschenes; Paul Coppo; Wolf Herman Fridman; Laurence Weiss Journal: J Am Soc Nephrol Date: 2004-03 Impact factor: 10.121
Authors: V Fremeaux-Bacchi; M-A Dragon-Durey; J Blouin; C Vigneau; D Kuypers; B Boudailliez; C Loirat; E Rondeau; W H Fridman Journal: J Med Genet Date: 2004-06 Impact factor: 6.318
Authors: Veronique Frémeaux-Bacchi; Elizabeth C Miller; M Kathryn Liszewski; Lisa Strain; Jacques Blouin; Alison L Brown; Nadeem Moghal; Bernard S Kaplan; Robert A Weiss; Karl Lhotta; Gaurav Kapur; Tej Mattoo; Hubert Nivet; William Wong; Sophie Gie; Bruno Hurault de Ligny; Michel Fischbach; Ritu Gupta; Richard Hauhart; Vincent Meunier; Chantal Loirat; Marie-Agnès Dragon-Durey; Wolf H Fridman; Bert J C Janssen; Timothy H J Goodship; John P Atkinson Journal: Blood Date: 2008-09-16 Impact factor: 22.113
Authors: Robert A Brodsky; Neal S Young; Elisabetta Antonioli; Antonio M Risitano; Hubert Schrezenmeier; Jörg Schubert; Anna Gaya; Luke Coyle; Carlos de Castro; Chieh-Lin Fu; Jaroslaw P Maciejewski; Monica Bessler; Henk-André Kroon; Russell P Rother; Peter Hillmen Journal: Blood Date: 2007-11-30 Impact factor: 22.113
Authors: Antoine Durrbach; Helene Francois; Severine Beaudreuil; Antoine Jacquet; Bernard Charpentier Journal: Nat Rev Nephrol Date: 2010-02-02 Impact factor: 28.314
Authors: Mercedes Cao; Tamara Ferreiro; Bruna N Leite; Francisco Pita; Luis Bolaños; Francisco Valdés; Angel Alonso; Eduardo Vázquez; Juan Mosquera; María Trigás; Santiago Rodríguez Journal: CEN Case Rep Date: 2017-03-01